top of page
Biopharma Over Coffee Blog
Updates on recent goings on in the pharma, biotech and healthcare sectors.
Scroll down to take a look at recent articles >>
Recent articles
ENGLAND'S SINGLE NATIONAL FORMULARY: WIN-WIN REFORM OR NEW MARKET ACCESS BOTTLENECK?
ANTI-AMYLOID DRUGS IN ALZHEIMER'S: BREAKTHROUGH, DEAD END, OR REIMBURSEMENT REALITY CHECK?
MFN PRICING AND THE “GLOBAL LAUNCH FREEZE”: A MORE MEASURED PERSPECTIVE
NICE, VPAG AND THE UK’S NEW SIGNAL TO PHARMA: PROGRESS AT LAST
MASH IN 2025: NEW THERAPIES, NEW CHALLENGES
CHINA'S NRDL: THE WORLD'S LARGEST MARKET ACCESS EVENT IS UNDERWAY
GLP-1S AND THE RISE OF CONSUMER-LED PHARMA: WHAT THE OBESITY MARKET SIGNALS FOR THE FUTURE OF ACCESS
MOST-FAVORED NATION DRUG PRICING: POLICY SHIFT OF PRESSURE TACTIC?
TRUMP'S DRUG PRICING EXECUTIVE ORDER: UNCERTAINTY FOR PHARMA LEADERS
TARIFFS ON PHARMACEUTICALS: ARE DRUG PRICES SET TO RISE?
ACCESS TO THE NEW ALZHEIMER'S DRUGS: WHY HTA BODIES ARE SAYING NO
TAKING ON THE ACCESS HURDLES FOR ORPHAN DRUGS: PREPARING FOR EU HTA
DISRUPTING HTA AND HEOR: THE ROLE OF AI
FINDING NEW TREATMENTS FOR ALS PATIENTS: A LOOK AT THE LATE-STAGE PIPELINE
EU HTA IS NOW LIVE: WHAT DO WE DO NOW?
TURNING SETBACKS INTO STRATEGIES: LESSONS FROM RELYVIRO’S JOURNEY IN ALS
DISEASE-MODIFYING DRUGS FOR PARKINSON'S DISEASE: A NEW WAVE ON THE HORIZON?
CHANGES IN MARKET ACCESS IN EUROPE: IMPLICATIONS FOR CLINICAL DEVELOPMENT PLANNING: JOINT CLINICAL ASSESSMENTS
BREAKING BARRIERS: TECELRA BECOMES THE FIRST ENGINEERED T-CELL FOR SOLID TUMOURS
KISUNLA: ANOTHER BREAKTHROUGH FOR ALZHEIMER'S DISEASE PATIENTS
A NEW TREATMENT PARADIGM FOR INFLAMMATORY CONDITIONS?
EU PHARMA REFORM IN FOCUS: IMPLICATIONS FOR INNOVATION AND ACCESS
THE NEXT WAVE OF PERSONALISATION: 3D PRINTING MEDICINES - PART 1
THE NEXT WAVE OF PERSONALISATION: 3D PRINTING MEDICINES - PART 2
EXPLORING KRAS MUTATIONS IN ONCOLOGY: CHALLENGES AND OPPORTUNITIES - PART 1
bottom of page